Physician profile
Eric Ewald
NPI 1700846805
$3,142.40
in general payments reported to CMS, 2019-2025
20 companies · $289 in 2025
The $289 reported for 2025 was more than what 75% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $431 · 2021: $608 · 2022: $430 · 2023: $489 · 2024: $547 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $574.19 | 2021-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $403.96 | 2019-2022 | |
| Pfizer INC. | $363.56 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.34 | 2019-2023 | Jardiance |
| Exact Sciences Corporation | $266.56 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $202.53 | 2019-2024 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $179.14 | 2022-2025 | |
| Lilly USA, LLC | $170.79 | 2020-2025 | Mounjaro, Emgality, Jardiance |
| Astellas Pharma US INC | $164.73 | 2024-2025 | Veozah |
| Eisai INC. | $124.46 | 2024 | |
| Amgen INC. | $94.56 | 2023-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $58.38 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $46.07 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.84 | 2022-2023 | Xarelto |
| Paratek Pharmaceuticals, INC. | $43.63 | 2023 | Nuzyra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $39.26 | 2023-2025 | Immunocap |
| Horizon Therapeutics Plc | $21.37 | 2021 | |
| Kaleo, INC. | $19.69 | 2019 | |
| Linus Health, INC. | $16.15 | 2024 | Core Cognitive Evaluation |
| Redhill Biopharma INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Ewald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.